Jonathan Stringer, MD
Endocrinology, Diabetes & Metabolism · Hot Springs, ARNPI 1275742884
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations.
Across 422 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$922
- Novo Nordisk$591
- Medtronic$546
- Boehringer Ingelheim$513
- Lilly USA, LLC$508
- Amgen$474
- plus $4K from 31 others
Across 5 payments — averaging $265.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Food & beverage$7,41099%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 72 | $922 |
| Novo Nordisk | 45 | $591 |
| Medtronic(2 entities) | 20 | $546 |
| Boehringer Ingelheim | 31 | $513 |
| Lilly USA, LLC | 27 | $508 |
| Amgen(2 entities) | 28 | $474 |
| Sanofi-aventis U.S. LLC | 25 | $404 |
| Dexcom, Inc. | 25 | $360 |
| AstraZeneca(2 entities) | 21 | $356 |
| Insulet Corporation | 12 | $269 |
| Tandem Diabetes Care, Inc. | 9 | $259 |
| Recordati_rare_diseases_inc. | 7 | $228 |
| Merck | 13 | $220 |
| Radius Health, Inc. | 11 | $219 |
| AbbVie | 10 | $213 |
| Mannkind Corporation | 6 | $161 |
| Antares Pharma, Inc. | 9 | $147 |
| Cequr Corporation | 2 | $126 |
| Corcept Therapeutics | 5 | $111 |
| BETA Bionics, Inc. | 4 | $93 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| Ascendis Pharma Endocrinology Inc | 4 | $79 |
| Bayer | 4 | $75 |
| Kyowa Kirin, Inc. | 3 | $66 |
| Halozyme Inc | 3 | $63 |
| IBSA Pharma Inc. | 4 | $57 |
| Sequel Med Tech, LLC | 3 | $55 |
| Amryt Pharma Holdings Ltd | 3 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Amarin Pharma, Inc. | 2 | $39 |
| Acella Pharmaceuticals, LLC | 2 | $37 |
| Chiesi USA, Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Roche Diabetes Care, Inc. | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$118
- FreeStyle Libre$115
How this compares
$7,464 in reported general payments places this provider in the 55th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 288 | $366,143 |
| OzempicSemaglutide | 196 | $216,887 |
| Tresiba Flextouch U-100Insulin Degludec | 230 | $153,568 |
| ForteoTeriparatide | 23 | $111,827 |
| JardianceEmpagliflozin | 117 | $102,308 |
| Tresiba Flextouch U-200Insulin Degludec | 88 | $100,163 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 65 | $65,795 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $61,991 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 13 | $57,605 |
| FarxigaDapagliflozin Propanediol | 72 | $55,722 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 20 | $47,604 |
| Novolog FlexpenInsulin Aspart | 171 | $47,581 |
| TrulicityDulaglutide | 43 | $41,116 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 91 | $36,984 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 71 | $36,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog | $508 | $529,907397 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $591 | $285,331280 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $513 | $120,822143 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $404 | $66,76494 claims |
| AstraZenecaFarxiga | $356 | $55,72272 claims |
| MerckJanuvia, Janumet Xr | $220 | $28,19847 claims |
| AbbVieSynthroid | $213 | $8,931106 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $4,248534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Hot Springs
- Daryl BurrowsHot Springs$29K
- Richard GriffithsLittle Rock$925K
- Catherine KilpatrickFayetteville$690K
- Adam MaassSpringdale$502K
- James ThrasherLittle Rock$349K
- Kevin GanongJonesboro$131K
- Cory GambleFort Smith$112K
- Chitharanjan DuvoorJonesboro$76K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.